Recombinant IL-37 treatment in the subsequent aging B-ALL mouse model significantly strengthened anti-leukemia T-cell-mediated immune responses via preventing PD-1 expression on T cells (75). Here, IL37 is linked to precursor B-cell acute lymphoblastic leukemia.